West Hill closes £5.5million investment in Neurescue, a pioneer of numerous world first innovations in medical history

West Hill is delighted to announce the addition of Neurescue to the portfolio, the developer of an unprecedented life-saving portable cardiac arrest device that has the potential to materially increase survival rates in patients suffering cardiovascular emergencies.

Cardiovascular disease is the single biggest cause of death globally, representing 31% of mortality, with cardiac arrest accounting for approximately 45% of these deaths. In emergency situations, time is critical and faster restoration of blood flow and oxygen to the heart and brain dramatically increases the chances of survival. Today’s CPR methods only replace around 35% of the required blood flow, which is insufficient to resuscitate most patients and fails to buy enough time to bridge most to other treatments. 

The Neurescue device is FDA cleared and is the world’s first intelligent balloon catheter for aortic occlusion, an emergency technique that supercharges blood flow to the heart and brain within two minutes from deployment. The catheter-based device is delivered via the femoral artery to temporarily inflate a soft balloon in the aorta, redirecting blood flow towards the upper body.

Utilised for emergency patients who have not responded to CPR, Neurescue leverages its handheld automated hardware and software technology to concentrate blood flow to the heart and brain, improving the chances for immediate resuscitation and extending the critical time window in which patients can receive additional treatments.

Having already achieved pivotal milestones, the capital raised will enable Neurescue to complete additional clinical studies toward commercialising this life-saving innovation. 

Furthermore, Neurescue’s next-generation product is a robotic automated arterial access device. This world first innovation is designed to work synergistically with the first product, facilitating the insertion of a soft, small, plastic sheath into the femoral artery when strapped onto a patient’s thigh, thereby enabling almost anyone to deliver the life-saving procedure and not just medical professionals.

This additional ground-breaking product could potentially become widely available in the same way as defibrillators are today, located in public spaces for anyone to use, performing life-saving procedures in critical situations. 

CEO and Founder, Dr. Habib Frost, commented:

‘We are delighted to have raised our Series A funding led by West Hill Capital. 

This incredible support demonstrates a shared vision in saving cardiac arrest and haemorrhage patients with our FDA cleared intelligent balloon system. 

Thank you to the team and our existing and new investors who support our mission.’